PATSOPOULOS, N.A, the BAYER PHARMA MS GENETICS WORKING GROUP, the STEERING COMMITTEES OF STUDIES EVALUATING IFN?-1B AND A CCR1-ANTAGONIST, the ANZGENE CONSORTIUM, GENEMSA, the INTERNATIONAL MULTIPLE SCLEROSIS GENETICS CONSORTIUM, ESPOSITO, F, REISCHL, J, LEHR, S, BAUER D, HEUBACH J, SANDBRINK R, POHL C, EDAN G, KAPPOS L, MILLER D, MONTALBÁN J, POLMAN CH, FREEDMAN MS, HARTUNG HP, ARNASON BG, COMI G, COOK S, FILIPPI M, GOODIN DS, JEFFERY D, O'CONNOR P, EBERS GC, LANGDON D, REDER AT, TRABOULSEE A, ZIPP F, SCHIMRIGK S, HILLERT J, BAHLO M, BOOTH DR, BROADLEY S, BROWN MA, BROWNING BL, BROWNING SR, BUTZKUEVEN H, CARROLL WM, CHAPMAN C, FOOTE SJ, GRIFFITHS L, KERMODE AG, KILPATRICK TJ, LECHNER-SCOTT J, MARRIOTT M, MASON D, MOSCATO P, HEARD RN, PENDER MP, PERREAU VM, PERERA D, RUBIO JP, SCOTT RJ, SLEE M, STANKOVICH J, STEWART GJ, TAYLOR BV, TUBRIDY N, WILLOUGHBY E, WILEY J, MATTHEWS P, BONESCHI FM, COMPSTON A, HAINES J, HAUSER SL, MCCAULEY J, IVINSON A, OKSENBERG JR, PERICAK-VANCE M, SAWCER SJ, , DE JAGER, P.L, HAFLER, D.A and DE BAKKER, P.I.
(2011)
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
Annals of Neurology, 70(6), 897-912.